Benefits
White-to-brown fat conversion
In mouse and cell studies, L-BAIBA dose-dependently induced 'browning' of white adipose tissue (WAT) — shifting energy-storing white fat toward thermogenic brown/beige fat that burns calories to generate heat (Roberts 2014). This browning effect has been demonstrated in animal models only; it has not been shown in humans.
Fat oxidation and body composition
In animal models, L-BAIBA increased free fatty-acid oxidation and reduced fat mass (~40% vs. control). This fat-loss effect is from animal data and has not been replicated in humans. The available human data is pharmacokinetic only — it confirms that plasma L-BAIBA rises within hours of oral dosing (absorption), not that fat oxidation or fat loss occurs in people.
Insulin sensitivity and glycogen storage
No human trial has demonstrated improved glycogen storage or insulin sensitivity for MitoBurn — the only human study was an acute (~5-hour) pharmacokinetic/absorption study, and glycogen supercompensation has been shown only in preclinical mouse studies. Effects on carbohydrate tolerance and insulin sensitivity via the AMPK-GLUT4 pathway are mechanistic/animal findings, not demonstrated human outcomes.
Mitochondrial health
In preclinical (animal/cell) studies, L-BAIBA stimulated mitochondrial biogenesis and ketone production, mechanisms that parallel adaptations seen with endurance exercise. These are mechanistic findings and have not been confirmed as clinical outcomes in humans.
Mechanism of action
PGC-1α myokine signaling
During exercise, PGC-1α activation in skeletal muscle triggers L-BAIBA synthesis and release into circulation. L-BAIBA then acts as a hormonal signal to adipose tissue, liver, and other organs — communicating that the body is in an exercise state and should optimize fat metabolism.
UCP1 upregulation in adipose tissue
L-BAIBA activates uncoupling protein 1 (UCP1) expression in white adipocytes, the defining molecular marker of brown/beige fat identity. UCP1 uncouples mitochondrial respiration from ATP synthesis, generating heat and burning calories instead.
AMPK activation and glucose metabolism
L-BAIBA activates AMPK in skeletal muscle and liver, stimulating glucose uptake via GLUT4 translocation, increasing fatty acid oxidation, and promoting glycogen supercompensation post-exercise.
Clinical trials
Randomized, double-blind, placebo-controlled crossover study of MitoBurn® (250, 500, 1,500 mg L-β-aminoisobutyric acid) vs placebo and L-valine in healthy adults. Outcomes: plasma L-BAIBA levels, kinetics. (2022)
Healthy adults. Acute crossover PK study.
All MitoBurn® doses produced dose-dependent increases in plasma L-BAIBA above baseline and above L-valine control. Establishes oral bioavailability and dosing parameters. Critical caveat: this is a PK study — does not establish clinical efficacy. Industry-funded.
Manufacturer-associated acute pharmacokinetic (~5-hour) crossover study of single oral doses (250/500/1500 mg L-BAIBA vs placebo and L-valine) measuring plasma absorption kinetics. This is an absorption/PK study only — it does not measure glycogen resynthesis, insulin sensitivity, or fat loss. Note: full peer-reviewed publication may be limited; primary documentation through NNB Nutrition.
12 healthy adults (6 men, 6 women, mean age 24). Randomized, double-blind, placebo-controlled crossover; single doses of placebo, 1500 mg L-valine, or 250/500/1500 mg MitoBurn® L-BAIBA, with 5-hour PK measurements.
L-BAIBA at 250, 500, and 1500 mg doses produced significantly greater plasma concentrations vs placebo or 1500 mg L-valine. Cmax was dose-dependent (B1500: 278 µM; B500: 95 µM; B250: 63 µM). Established absorption kinetics for oral L-BAIBA supplementation. No clinically significant adverse events. Note: glycogen supercompensation claims come from preclinical mouse studies, not this trial.